Contemporary Pharmacological Treatment of Heart Failure

In the last decades heart failure was perceived as a fatal disease with a very poor prognosis. However, recent developments in the pharmacotherapy of chronic heart failure with reduced ejection fraction have completely changed the natural history of this clinical syndrome. The implementation into clinical practice the neurohormonal antagonists (angiotensin converting enzyme inhibitors, beta-blockers, angiotensin receptor antagonists and mineralocorticoid receptor antagonists) should be viewed as the major breakthrough in the management of chronic heart failure. In only last few years two new drug classes: If- channel inhibitor and angiotensin receptor neprilysin inhibitor, have been found to further improve the outcomes of these patients. Nowadays by applying all evidence-based discoveries for heart failure management, it is becoming preventable and treatable disease.